Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Chief Medical Officer | October 13, 2023 | October 17, 2023 |
| Lantheus Holdings, Inc.LNTH · Entity 690 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date October 13, 2023 · Filed October 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.31 · Expires 2033-10-13 | Direct | 16,667 |
Reported balance
After 2023-10-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-10-13 · Grant · Acquired 16,667 · Balance 16,667 F1: This option was granted on October 13, 2023 with respect to 16,667 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on October 13, 2023 with respect to 16,667 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.
Lantheus Holdings, Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,237 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 4,137 · Balance 7,237 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 18, 2026 20:37 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 4,137 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000210 · form4.xml · nonDerivative · entry 1 Morrow Phuong Khanh · CIK 0001928989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,237 Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:41 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 4,543 | $0.00 Strike: $78.81 | $0.00 |
DisclosureSEC source: 0001062993-25-009698 · form4.xml · derivative · entry 2 Morrow Phuong Khanh · CIK 0001928989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,543 Underlying: Common Stock · 4,543 shares Expires 2035-05-14 Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:41 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-009698 · form4.xml · nonDerivative · entry 1 Morrow Phuong Khanh · CIK 0001928989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,100 Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 21:31 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 1,017 | $0.00 Strike: $88.71 | $0.00 |
DisclosureSEC source: 0001062993-25-002103 · form4.xml · derivative · entry 2 Morrow Phuong Khanh · CIK 0001928989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,017 Underlying: Common Stock · 1,017 shares Expires 2035-02-07 Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 21:31 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 563 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-002103 · form4.xml · nonDerivative · entry 1 Morrow Phuong Khanh · CIK 0001928989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 563 Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 22:15 UTC Amendment | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 1,015 | $0.00 Strike: $88.71 | $0.00 |
DisclosureSEC source: 0001062993-25-002208 · form4a.xml · derivative · entry 1 Morrow Phuong Khanh · CIK 0001928989 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,015 Underlying: Common Stock · 1,015 shares Expires 2035-02-07 F1 · shares: The Form 4 originally filed on February 11, 2025, inadvertently reported 1,017 options granted on February 7, 2025, due to an administrative error. The correct number of options granted on February 7, 2025, is 1,015 and is being reported in this amendment. F1 · derivative.underlying_shares: The Form 4 originally filed on February 11, 2025, inadvertently reported 1,017 options granted on February 7, 2025, due to an administrative error. The correct number of options granted on February 7, 2025, is 1,015 and is being reported in this amendment. F1 · balance_after: The Form 4 originally filed on February 11, 2025, inadvertently reported 1,017 options granted on February 7, 2025, due to an administrative error. The correct number of options granted on February 7, 2025, is 1,015 and is being reported in this amendment. Read SEC document |
| October 13, 2023 Filed Oct 17, 2023 21:52 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 16,667 | $0.00 Strike: $44.31 | $0.00 |
DisclosureSEC source: 0000950170-23-053819 · ownership.xml · derivative · entry 1 Morrow Phuong Khanh · CIK 0001928989 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Shares · 16,667 shares Expires 2033-10-13 F1 · derivative.exercise_date: This option was granted on October 13, 2023 with respect to 16,667 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023. Read SEC document |
| May 24, 2023 Filed May 25, 2023 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 2,527 | $65.91 | $166,554.57 |
DisclosureSEC source: 0001209191-23-032250 · doc4.xml · nonDerivative · entry 2 Morrow Phuong Khanh · CIK 0001928989 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,411 F3 · kind: On May 23, 2022, the reporting person was granted 27,750 restricted stock units. On May 23, 2023, 6,938 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 23, 2023 Filed May 25, 2023 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 6,938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-032250 · doc4.xml · derivative · entry 3 Morrow Phuong Khanh · CIK 0001928989 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,812 Underlying: Common Shares · 6,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · derivative.exercise_date: The restriced stock units shall vest as follows: (i) one quarter of the shares shall vest on May 23, 2023, (ii) one quarter of the shares shall vest on May 23, 2024, (iii) one quarter of the shares shall vest on May 23, 2025, and (iv) one quarter of the shares shall vest on May 23, 2026. F1 · derivative.expiration_date: The restriced stock units shall vest as follows: (i) one quarter of the shares shall vest on May 23, 2023, (ii) one quarter of the shares shall vest on May 23, 2024, (iii) one quarter of the shares shall vest on May 23, 2025, and (iv) one quarter of the shares shall vest on May 23, 2026. Read SEC document |
| May 23, 2023 Filed May 25, 2023 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 6,938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-032250 · doc4.xml · nonDerivative · entry 1 Morrow Phuong Khanh · CIK 0001928989 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restriced stock units shall vest as follows: (i) one quarter of the shares shall vest on May 23, 2023, (ii) one quarter of the shares shall vest on May 23, 2024, (iii) one quarter of the shares shall vest on May 23, 2025, and (iv) one quarter of the shares shall vest on May 23, 2026. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018561 · doc4.xml · derivative · entry 2 Morrow Phuong Khanh · CIK 0001928989 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Shares · 22,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 44,620 | $0.00 Strike: $43.22 | $0.00 |
DisclosureSEC source: 0001209191-23-018561 · doc4.xml · derivative · entry 1 Morrow Phuong Khanh · CIK 0001928989 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,620 Underlying: Common Shares · 44,620 shares Expires 2033-03-10 F1 · derivative.exercise_date: This option was granted on March 10, 2023 with respect to 44,620 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2023. Read SEC document |
| October 07, 2022 Filed Oct 12, 2022 21:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 9,380 | $0.00 Strike: $61.65 | $0.00 |
DisclosureSEC source: 0001209191-22-053496 · doc4.xml · derivative · entry 1 Morrow Phuong Khanh · CIK 0001928989 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,380 Underlying: Common Shares · 9,380 shares Expires 2032-10-07 F1 · derivative.exercise_date: This option was granted on October 7, 2022 with respect to 9,380 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 7, 2022. Read SEC document |
| May 23, 2022 Filed May 24, 2022 21:55 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $54.71 | $0.00 |
DisclosureSEC source: 0001209191-22-031705 · doc4.xml · derivative · entry 2 Morrow Phuong Khanh · CIK 0001928989 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Shares · 90,000 shares Expires 2032-05-23 F3 · derivative.exercise_date: This option was granted on May 23, 2022 with respect to 90,000 Common Shares, with 25% of the shares vesting on May 23, 2023 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months. Read SEC document |
| May 23, 2022 Filed May 24, 2022 21:55 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 27,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031705 · doc4.xml · derivative · entry 1 Morrow Phuong Khanh · CIK 0001928989 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,750 Underlying: Common Shares · 27,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: This restricted stock unit award was granted on May 23, 2022 with respect to 27,750 Common Shares, with (i) one quarter of the shares vesting on May 23, 2023, (ii) one quarter of the shares vesting on May 23, 2024, (iii) one quarter of the shares vesting on May 23, 2025, and (iv) one quarter of the shares vesting on May 23, 2026. F2 · derivative.expiration_date: This restricted stock unit award was granted on May 23, 2022 with respect to 27,750 Common Shares, with (i) one quarter of the shares vesting on May 23, 2023, (ii) one quarter of the shares vesting on May 23, 2024, (iii) one quarter of the shares vesting on May 23, 2025, and (iv) one quarter of the shares vesting on May 23, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.